<DOC>
	<DOCNO>NCT01774032</DOCNO>
	<brief_summary>The purpose study obtain immunogenicity safety data H5N1 pandemic influenza vaccine Japanese elderly population age 65 year old .</brief_summary>
	<brief_title>H5N1 Vaccine Study Japanese Elderly Population Aged 65 Years Older</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participant 65 year old time screen . Participant generally healthy , determine investigator 's clinical judgment collection medical history performance physical examination . Participant physically mentally capable participate study . Participant willing able comply requirement protocol . Participant history infection H5N1 virus history vaccination H5N1 influenza vaccine . Participant high risk contract H5N1 influenza infection ( e.g. , poultry worker ) . Participant currently history significant cardiovascular ( include hypertension ) , respiratory ( include asthma ) , metabolic , neurological ( include GuillainBarr√© Syndrome acute disseminate encephalomyelitis ) , hepatic , rheumatic , autoimmune , hematological , gastrointestinal renal disorder . Participant inherit acquired immunodeficiency . Participant disease currently undergoing form treatment undergoing form treatment within 30 day prior study entry expect influence immune response . Such treatment include , limited : systemic inhaled corticosteroid , radiation treatment immunosuppressive cytotoxic drug . Participant history severe allergic reaction anaphylaxis . Participant rash , dermatologic condition tattoo may interfere injection site reaction rating . Participant receive blood transfusion immunoglobulin within 90 day prior study entry . Participant donate blood plasma within 30 day prior study entry . Participant receive influenza live vaccine within 4 week inactivate vaccine within 2 week prior vaccination study . Participant functional surgical asplenia . Participant know suspect problem alcohol drug abuse . Participant expose investigational product ( IP ) within 30 day prior enrollment schedule participate another clinical study involve IP investigational device course study . Participant family member employee investigator . Participant condition disqualifies his/her participation study opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>